Surprisingly, the frequency of tumor-associated MDSCs was not decreased in CCR2 antagonist-treated mice, but the MDSCs now displayed significantly lower levels of CCR2 expression and had an M1 phenotype. The gene discussed is CCR2; the disease is neoplasm.